Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: a metanalysis

Glucagon-like peptide-1 (GLP-1) agonists improve glycemic control in type 2 diabetes mellitus (DM). Outcome trials investigating macro and microvascular effects of GLP-1 agonists reported conflicting results. The aim of this study was to assess, in a metanalysis, the effects of GLP-1 agonists on mortality, major nonfatal cardiovascular (CV) events, renal and retinal events.

Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - September 26, 2017 Category: Nutrition Authors: P. Gargiulo, G. Savarese, C. D ’Amore, F. De Martino, L.H. Lund, F. Marsico, S. Dellegrottaglie, C. Marciano, B. Trimarco, P. Perrone-Filardi Source Type: research